The specialty pharmaceutical company ProStrakan Group has received approval from EMA to market Sancuso (granisetron transdermal system) in the European Union, with 3M Drug Delivery Systems acting as the manufacturer. ProStrakan began marketing the product in October 2013 in the United Kingdom, Germany, and the Netherlands. Additional European countries are expected to be added in 2014.
Initially introduced in the United States in 2008, Sancuso is used to treat chemotherapy-induced nausea and vomiting. The transdermal patch is applied to the upper arm and can be worn for seven days, providing continuous transdermal delivery and eliminating the need to take pills daily to control nausea and vomiting.
ProStrakan previously relied on a different manufacturer for the US supply of Sancuso. FDA approval is currently pending for the 3M Drug Delivery Systems manufactured product.
Source: 3M Drug Delivery Systems
